Prognostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor and High-Sensitivity C-Reactive Protein on Postoperative Mortality in Patients Undergoing Elective On-Pump Cardiac Surgery

Published:November 01, 2020DOI:


      Elevated soluble urokinase-type plasminogen activator receptor (suPAR) and high-sensitivity C-reactive protein (hsCRP) have been associated with increased mortality in patients with cardiovascular disease. The aim of the present study was to explore the relationship between suPAR and hsCRP values and associated mortality after elective cardiac surgery. A secondary aim was to assess whether a combined risk model of European System for Cardiac Operative Risk Evaluation (EuroSCORE II), suPAR, and/or hsCRP would improve the prognostic accuracy compared with EuroSCORE II alone.


      Retrospective observational study.


      Single-center, university hospital.


      Adult patients admitted for elective on-pump cardiac surgery were included. Biobank blood samples were obtained from previous research projects at a tertiary heart center from 2012 to 2018.



      Measurements and Main Results

      A total of 931 patients were included. Kaplan-Meier and Cox proportional hazard analyses were used to explore a potential association between preoperative suPAR and hsCRP values and all-cause mortality up to one year after surgery. Thirty-day mortality was predicted from suPAR, hsCRP, and EuroSCORE II by logistic regression and compared using area under the receiver operating characteristics curve and Brier scores. After adjustment for known confounders, a doubling of suPAR and hsCRP corresponded to a hazard ratio for all-cause mortality of 2.27 (95% confidence interval 1.65-3.11; p < 0.001) and 1.26 (95% confidence interval 1.07-1.49; p = 0.005), respectively. However, adding the biomarkers to EuroSCORE II did not improve prediction/discrimination with respect to 30-day mortality.


      Elevated preoperative levels of suPAR and hsCRP were associated with all-cause mortality in elective cardiac surgery patients. However, inclusion of biomarkers did not improve the prognostic accuracy of EuroSCORE II.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiothoracic and Vascular Anesthesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Bonnet V
        • Boisselier C
        • Saplacan V
        • et al.
        The role of age and comorbidities in postoperative outcome of mitral valve repair: A propensity-matched study.
        Medicine (Baltimore). 2016; 95: e3938
        • Nashef SAM
        • Roques F
        • Sharples LD
        • et al.
        EuroSCORE II.
        Eur J Cardiothorac Surg. 2012; 41: 734-745
        • Laffey JG
        • Boylan JF
        • Cheng DCH
        The systemic inflammatory response to cardiac surgery: Implications for the anesthesiologist.
        Anesthesiology. 2002; 97: 215-252
        • Karkouti K
        • Wijeysundera DN
        • Yau TM
        • et al.
        Acute kidney injury after cardiac surgery.
        Circulation. 2009; 119: 495-502
        • Kertai MD
        • Li Y-J
        • Li Y-W
        • et al.
        Genome-wide association study of perioperative myocardial infarction after coronary artery bypass surgery.
        BMJ Open. 2015; 5e006920
        • Lyngbaek S
        • Marott JL
        • Moller D V
        • et al.
        Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention.
        Am J Cardiol. 2012; 110: 1756-1763
        • Hodges GW
        • Bang CN
        • Eugen-Olsen J
        • et al.
        SuPAR predicts cardiovascular events and mortality in patients with asymptomatic aortic stenosis.
        Can J Cardiol. 2016; 32: 1462-1469
        • Lyngbaek S
        • Andersson C
        • Marott JL
        • et al.
        Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain.
        Clin Chem. 2013; 59: 1621-1629
        • Meyer J
        • Alstrup M
        • Rasmussen LJH
        • et al.
        suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patients.
        Scand J Trauma Resusc Emerg Med. 2018; 26: 11
        • Sörensen NA
        • Nikorowitsch J
        • Neumann JT
        • et al.
        Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction.
        Clin Res Cardiol. 2019; 108: 1386-1393
        • Eugen-Olsen J
        • Andersen O
        • Linneberg A
        • et al.
        Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population.
        J Intern Med. 2010; 268: 296-308
        • Diederichsen MZ
        • Diederichsen SZ
        • Mickley H
        • et al.
        Prognostic value of suPAR and hs-CRP on cardiovascular disease.
        Atherosclerosis. 2018; 271: 245-251
        • Persson M
        • Engstrom G
        • Bjorkbacka H
        • et al.
        Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmo Diet and Cancer Study.
        Atherosclerosis. 2012; 220: 502-505
        • Frary CE
        • Blicher MK
        • Olesen TB
        • et al.
        Circulating biomarkers for long-term cardiovascular risk stratification in apparently healthy individuals from the MONICA 10 cohort.
        Eur J Prev Cardiol. 2020; 27: 570-578
        • Balciunas M
        • Bagdonaite L
        • Samalavicius R
        • et al.
        Pre-operative high sensitive C-reactive protein predicts cardiovascular events after coronary artery bypass grafting surgery: A prospective observational study.
        Ann Card Anaesth. 2009; 12: 127-132
        • Wang J
        • Zheng Z
        • Yang L
        • et al.
        High-sensitive C-reactive protein predicts outcome after coronary artery bypass.
        Asian Cardiovasc Thorac Ann. 2012; 20: 525-533
        • Kosmidou I
        • Redfors B
        • Chen S
        • et al.
        C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial.
        Am Heart J. 2019; 210: 49-57
        • Han SS
        • Kim DK
        • Kim S
        • et al.
        C-reactive protein predicts acute kidney injury and death after coronary artery bypass grafting.
        Ann Thorac Surg. 2017; 104: 804-810
        • Perry TE
        • Muehlschlegel JD
        • Liu K-Y
        • et al.
        Preoperative C-reactive protein predicts long-term mortality and hospital length of stay after primary, nonemergent coronary artery bypass grafting.
        Anesthesiology. 2010; 112: 607-613
        • Hodges GW
        • Bang CN
        • Eugen-Olsen J
        • et al.
        SuPAR predicts postoperative complications and mortality in patients with asymptomatic aortic stenosis.
        Open Heart. 2018; 5e000743
        • Riisbro R
        • Christensen IJ
        • Hogdall C
        • et al.
        Soluble urokinase plasminogen activator receptor measurements: Influence of sample handling.
        Int J Biol Markers. 2001; 16: 233-239
        • Nilsson TK
        • Boman K
        • Jansson J-H
        • et al.
        Comparison of soluble thrombomodulin, von Willebrand factor, tPA/PAI-1 complex, and high-sensitivity CRP concentrations in serum, EDTA plasma, citrated plasma, and acidified citrated plasma (Stabilyte) stored at −70°C for 8-11 years.
        Thromb Res. 2005; 116: 249-254
        • Kofoed K
        • Schneider UV
        • Scheel T
        • et al.
        Development and validation of a multiplex add-on assay for sepsis biomarkers using xMAP technology.
        Clin Chem. 2006; 52: 1284-1293
        • Hlatky MA
        • Greenland P
        • Arnett DK
        • et al.
        Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American Heart Association.
        Circulation. 2009; 119: 2408-2416
        • Holm J
        • Vidlund M
        • Vanky F
        • et al.
        EuroSCORE II and N-terminal pro-B-type natriuretic peptide for risk evaluation: An observational longitudinal study in patients undergoing coronary artery bypass graft surgery.
        Br J Anaesth. 2014; 113: 75-82
        • Lyngbaek S
        • Marott JL
        • Sehestedt T
        • et al.
        Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score.
        Int J Cardiol. 2013; 167: 2904-2911
        • Hodges GW
        • Bang CN
        • Wachtell K
        • et al.
        suPAR: A new biomarker for cardiovascular disease?.
        Can J Cardiol. 2015; 31: 1293-1302
        • Thunø M
        • Macho B
        • Eugen-Olsen J
        suPAR: The molecular crystal ball.
        Dis Markers. 2009; 27: 157-172
        • Desmedt S
        • Desmedt V
        • Delanghe JR
        • et al.
        The intriguing role of soluble urokinase receptor in inflammatory diseases.
        Crit Rev Clin Lab Sci. 2017; 54: 117-133
        • Lyngbaek S
        • Sehestedt T
        • Marott JL
        • et al.
        CRP and suPAR are differently related to anthropometry and subclinical organ damage.
        Int J Cardiol. 2013; 167: 781-785
        • Gozdzik W
        • Adamik B
        • Gozdzik A
        • et al.
        Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use.
        PLoS One. 2014; 9: e98923
        • Drakopoulou M
        • Toutouzas K
        • Stefanadi E
        • et al.
        Association of inflammatory markers with angiographic severity and extent of coronary artery disease.
        Atherosclerosis. 2009; 206: 335-339
        • Yousuf O
        • Mohanty BD
        • Martin SS
        • et al.
        High-sensitivity C-reactive protein and cardiovascular disease: A resolute belief or an elusive link?.
        J Am Coll Cardiol. 2013; 62: 397-408
        • Biancari F
        • Lahtinen J
        • Lepojarvi S
        • et al.
        Preoperative C-reactive protein and outcome after coronary artery bypass surgery.
        Ann Thorac Surg. 2013; 76: 2007-2012
        • McCormack JP
        • Allan GM
        Measuring hsCRP - an important part of a comprehensive risk profile or a clinically redundant practice?.
        PLoS Med. 2010; 7e1000196
        • Ghasemzedah N
        • Hayek SS
        • Ko Y-A
        • et al.
        Pathway-specific aggregate biomarker risk score is associated with burden of coronary artery disease and predicts near-term risk of myocardial Infarction and death.
        Circ Cardiovasc Qual Outcomes. 2017; 10e001493
        • Al-Badri A
        • Tahhan AS
        • Sabbak N
        • et al.
        Soluble urokinase-type plasminogen activator receptor and high-sensitivity troponin levels predict outcomes in nonobstructive coronary artery disease.
        J Am Heart Assoc. 2020; 9e015515
        • Nikorowitsch J
        • Borchardt T
        • Appelbaum S
        • et al.
        Cardio-renal biomarker soluble urokinase-type plasminogen activator receptor is associated with cardiovascular death and myocardial infarction in patients with coronary artery disease independent of troponin, C-reactive protein, and renal function.
        J Am Heart Assoc. 2020; 9e015452
        • Ichihara N
        • Miyamura M
        • Maeda D
        • et al.
        Association between serum soluble urokinase-type plasminogen activator receptor and atrial fibrillation.
        J Arrhythmia. 2017; 33: 469-474